View Older Stories View More Recent Stories

May 13, 2024 07:00AM Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 10, 2024 08:00AM Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024
May 3, 2024 04:45PM Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 12, 2024 08:00AM Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
Apr 5, 2024 09:00AM Praxis Precision Medicines to Participate in Upcoming April Conferences
Apr 2, 2024 05:00PM Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 26, 2024 06:31AM Praxis Precision Medicines (PRAX) Reports Positive Results of PRAX-628 Study
Mar 26, 2024 06:30AM Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
Mar 25, 2024 04:01PM Praxis Precision Medicines to Host PRAX-628 Program Update
Mar 5, 2024 07:00AM Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
Mar 1, 2024 08:00AM Praxis Precision Medicines to Participate in TD Cowen’s 44th Annual Health Care Conference
Feb 2, 2024 04:00PM Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 8, 2024 08:00AM Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio
Jan 5, 2024 08:05AM Praxis Precision Medicines (PRAX) Announces Licensing and Collaboration Agreement with Tenacia Biotechnology for Ulixacaltamide in Greater China
Jan 5, 2024 08:00AM Praxis Precision Medicines Announces Licensing and Collaboration Agreement with Tenacia Biotechnology for Ulixacaltamide in Greater China
Nov 28, 2023 07:00AM Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings
Nov 21, 2023 04:00PM Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare Conference
Nov 16, 2023 08:02AM Praxis Precision Medicines (PRAX) Receives PRIME Designation from the EMA for elsunersen
Nov 16, 2023 08:00AM Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies
Nov 7, 2023 07:00AM Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Nov 2, 2023 08:00AM Praxis Precision Medicines to Present at Truist Securities BioPharma Symposium
Oct 2, 2023 01:17PM Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day
Sep 27, 2023 04:15PM Praxis Precision Medicines To Host Hybrid R&D Day on Monday, October 2, 2023
Sep 7, 2023 08:00AM Praxis Precision Medicines to Present at H.C. Wainwright 25th Annual Global Investment Conference
Aug 31, 2023 08:00AM Praxis Precision Medicines to Present Data from Epilepsy Portfolio at the 35th International Epilepsy Congress
Aug 28, 2023 07:00AM Praxis Precision Medicines to Present Analyses of Patient-Focused, Clinically Meaningful Endpoints from Essential1 Study of Ulixacaltamide in Essential Tremor at the 2023 MDS International Congress
Aug 9, 2023 07:00AM Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Aug 8, 2023 07:03AM Praxis Precision Medicines (PRAX) Announces Positive Data from Randomized Withdrawal Sub-Study and Long-Term Extension of Essential1 Study for Ulixacaltamide
Aug 8, 2023 07:00AM Praxis Precision Medicines Announces Positive Data from Randomized Withdrawal Sub-Study and Long-Term Extension of Essential1 Study for Ulixacaltamide
Aug 7, 2023 07:07AM Praxis Precision Medicines (PRAX) Announces Positive Results of EEG Analysis of PRAX-628 Phase 1 Study
Aug 7, 2023 07:00AM Praxis Precision Medicines Announces Positive Results of EEG Analysis of PRAX-628 Phase 1 Study
Aug 3, 2023 04:12PM Praxis Precision Medicines to Participate at the 2023 Wedbush PacGrow Healthcare Conference
Jun 22, 2023 07:00AM Praxis Precision Medicines Announces Closing of Financing and Reiterates Corporate Priorities
Jun 9, 2023 07:03AM Praxis Precision Medicines (PRAX) Announces Plans to Begin Ulixacaltamide Phase 3 in Essential Tremor by Year End After Completing End of Phase 2 Meeting with FDA
Jun 9, 2023 07:00AM Praxis Precision Medicines Announces Plans to Begin Ulixacaltamide Phase 3 in Essential Tremor by Year End After Completing End of Phase 2 Meeting with FDA
Jun 2, 2023 09:00AM Praxis Precision Medicines to Present at the 2023 Jefferies Healthcare Conference
May 11, 2023 07:30AM Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 11, 2023 06:55AM Praxis Precision Medicines (PRAX) Announces Positive Topline Results from PRAX-628 Phase 1 Study
May 11, 2023 06:55AM Praxis Precision Medicines Announces Positive Topline Results from PRAX-628 Phase 1 Study Enabling Best-in-Class Profile
Apr 19, 2023 08:00AM Praxis Precision Medicines to Present at the American Academy of Neurology 2023 Annual Meeting
Apr 17, 2023 08:00AM Praxis Precision Medicines Announces Upcoming Ulixacaltamide Presentations & Events
Apr 6, 2023 09:00AM Praxis Precision Medicines to Present at 22nd Annual Needham Virtual Healthcare Conference
Mar 3, 2023 04:05PM Praxis Precision Medicines to Present at Upcoming Investor Conferences
Mar 3, 2023 07:30AM Praxis Precision Medicines (PRAX) Announces Topline Results from the Essential1 Study of Ulixacaltamide for the Treatment of Essential Tremor and Continued Advancement of Program to Phase 3
Mar 3, 2023 07:30AM Praxis Precision Medicines Announces Topline Results from the Essential1 Study of Ulixacaltamide for the Treatment of Essential Tremor and Continued Advancement of Program to Phase 3
Feb 7, 2023 08:00AM Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Dec 13, 2022 04:07PM Praxis Precision Medicines (PRAX) and UCB Announce Epilepsy Research Collaboration
Dec 13, 2022 04:01PM Praxis Precision Medicines and UCB Announce Epilepsy Research Collaboration
Nov 28, 2022 04:05PM Praxis Precision Medicines to Present at the American Epilepsy Society 2022 Annual Meeting
Nov 28, 2022 08:03AM Praxis Precision Medicines (PRAX) to Initiate PRAX-562 Phase 2 EMBOLD Study in DEEs
View More Recent Stories View Older Stories